University of California San Francisco Prepared: May 2010

CURRICULUM VITAE Name: Krystof S. Bankiewicz Position: Professor in Residence Department of Neurological Surgery and Neurology Address: Neurosurgery Department, UCSF, Mission Center Building Room 226, 1855 Folsom Street San Francisco, CA 94103 Voice: 415-502-3132 Fax: 415-514-2777 Email: krystof.bankiewicz@ucsf.edu Web: http://neurosurgery.ucsf.edu/bankiewicz/ EDUCATION: University Degrees: 1983 M.D. Jagiellonian University, Krakow, Poland 1996 Ph.D. Institute of Neurology and Psychiatry, Warszawa, Poland Thesis: “Experimental Studies Using Tissue Implantation for Treatment of Parkinson’s Disease” Training: 1983 Medical License 1983-1984 Internship in General Surgery, Medical Academy of Warszawa, Poland. 1983-1985 Resident, Neuroorthopedic Postgraduate Medical Center, Warszawa, Poland. 1985-1988 Post-doctoral Fellowship, Surgical Neurology, NINDS, NIH, Bethesda, MD Awards: 1985 Fogarty Fellowship, National Institutes of Health, Bethesda, Maryland 1999 Patent Award, NINDS, NIH, Bethesda, Maryland 2000 Special Act or Service Award, NINDS, NIH, Bethesda, Maryland 2002 Drug Development Prize, Academy of Molecular Imaging 2007 Presidential Presentation, American Society of Gene Therapy 2008 Honorary Member, Polish Academy of Neurology Academic & Research Position Held: 2009 Kinetics Foundation Chair in Translational Research, UCSF, San Francisco, CA. 2008- Professor In Residence, Neurology Department, UCSF, San Francisco, CA. 2002- Professor In Residence, Neurosurgery Department, UCSF, San Francisco, CA. 1998-2002 Associate Professor In Residence, Neurosurgery Department, UCSF, San

Francisco, CA.* *98-00 - Adjunct series; - 01-02 In Residence series

1997-2001 Acting Chief, Molecular Therapeutics Section, NINDS, NIH, Bethesda, MD 1994- Visiting Scientist, Laboratory for Functional Imaging, Lawrence Berkeley

National Laboratory, University of California, Berkeley, CA.

Krystof Bankiewicz

2

1994-1997 Director, Division of CNS Implantation and Regeneration, The Parkinson’s Institute, Sunnyvale, CA

1992-1997 Chief, Preclinical Studies, Somatix Therapy Corporation, Alameda, CA. 1991-1993 Chief, CNS Implantation Unit, Surgical Neurology Branch, NINDS, NIH Bethesda, MD. 1992-1993 Special Volunteer, Surgical Neurology Branch, NINDS, NIH,

Bethesda, MD. 1991-1992 Visiting Scientist, Surgical Neurology Branch. NINDS, NIH, Bethesda, MD. 1988-1991 Visiting Associate Scientist, Surgical Neurology Branch, NINDS, NIH, Bethesda,

MD. 1985-1988 Visiting Fellow, Surgical Neurology Branch, NINDS, NIH, Bethesda, MD. 1983-1985 Assistant Professor, Post-graduate Medical Center, Warszawa, Poland. 1980-1983 Research Associate, Department of Hematology and Internal Medicine, Medical

School, Jagiellonian University, Krakow, Poland PROFESSIONAL ACTIVITIES Meetings/Societies: 1992 Member of Local Organizing Committee - IVth International Symposium on Neural Transplantation, Washington, DC 1994-1996 Member of Scientific Program Committee - American Society for Neural Transplantation, Clearwater, FL 1995 Member of Organizing Committee - Cellular and Molecular Treatments of Neurological Diseases, Harvard Medical School, Boston, MA 1996 Member of International Organizing Committee - VIth International Symposium on Neural Transplantation, San Diego, CA 1996 Member of Organizing and Program Committee - International Symposium on

Cell and Gene Therapy in Parkinson’s and Other Neurological Disorders Beijing, China

1997-1999 Counselor, American Society for Neural Transplantation and Repair 1999 International Scientific Organizing Committee - VIIth International Symposium on Neural Transplantation, Denmark 1999-2002 Chairman, Finance Committee, American Society for Neural Transplantation and

Repair 1999 Member, American Society for Experimental NeuroTherapeutics 1999 Fellow, American Society for Neural Transplantation and Repair. 2004-2007 Member, Neural Disorders Committee, American Society of Gene Therapy 2004 Organizer, Local Brain Delivery of Therapeutics Workshop, The Kinetics

Foundation Palo Alto, April 23-24, 2005 Member, Society for Neuro-Oncology 2006-2010 Coordinating Reviewer for the Abstract, American Society of Gene Therapy Grant/Project Reviews: 2000 Member, US Army Medical Research Command Review Panel C 2000-03 Member, Veterans Administration Review Subcommittee for Neurobiology

Krystof Bankiewicz

3

1999 Member, Initial Review Board of the Medical and Scientific Advisory Council, Alzheimer’s Association.

1998 Member, US Army Medical Research Command Review Panel 1998-01 Member of the NIH, NINDS Animal Care and Use Committee. 1994 Ad Hoc Member, NINDS, NIH Study Section/ 1993 Chairperson, Ad Hoc Study Section Site Visit, NAI, NIH (AG1349401A1) 1995 Ad Hoc Member, NAI, NIH Study Section Site Visit (AG13494-01) 1990 Special Expert, NIH Grant Review Registry 1988 Ad Hoc Member, NINDS, NIH Study Section 1989-91 Member of the NIH, NINDS Animal Care and Use Committee. 2003- Member, Committee on Animals Research, UCSF 2004- Member, NINDS Udall Center Review Panel ZNS1 SRB-M (05) 2004- Member, NINDS Udall Center Review Panel ZNS1 SRB-M (12) 2005- Ad Hoc, NINDS Study Section, Preclinical Studies of Gene Therapy for Parkinson’s Disease ZNS1 SRB-G (02) 2005 NINDS Special Emphasis Panel ZNS1 SRB-G (02) 2006 Scientific Reviewer, Michael J. Fox Foundation 2006 NINDS Brain Disorders and Clinical Neurosciences Study Section, ZRG1 BDCN-N 02 M 2009 NINDS Udall Center Review Study Section 2009 NINDS Neurological Sciences and Disorders K 2010 Gene and Drug Delivery (GDD) Study Section 2010 Cell Death in Neurodegeneration (CDIN) Study Section Editorial Boards: 2009- Medycyna Praktyczna -Neurologia 2009- NeuroImage 2006- Neuro-Oncology 1999- Experimental Neurology 1993-1998 Journal of Neural Transplantation and Plasticity Ad Hoc Referee: Experimental Neurology, Movement Disorders, Journal of Neurochemistry, Life Science, Brain Research, Cell Transplantation, Molecular Therapy, Neurobiology of Aging, Cancer Research, Journal of Neuroscience, Journal of Comparative Neurology, The Wellcome Trust Foundation, PNAS, Expert Reviews in Molecular Medicine, European Journal of Neuroscience, Human Gene Therapy, NeuroOncology, Nature. Consulting: 2001-04 Scientific Advisory Board, Avigen Inc. 2003-06 Scientific Advisor, Genzyme Corporation. 2002-06 Scientific Advisor, Merck Inc. 2002-05 Scientific Advisory Board, Oxford Biomedica Inc. 2004-06 Clinical Advisory Board, Sirna Therapeutics

Krystof Bankiewicz

4

2006- Scientific Advisory Board, MedGenesis Therapeutics Invited Lectures: 07/03/87 Schmitt International Neurological Sciences Symposium.

Invited Speaker: Adrenal medulla allograft implants produce transient behavioral recovery in hemiparkinsonian monkeys

01/ 25/88 Winter Conference on Brain Research. Invited Speaker: Tissue transplantation into brain as a treatment for Parkinson's syndrome in monkeys and man.

02/24/88 Howard University, Department of Pharmacology Invited Lecturer: Brain Implants in Parkinsonism 05/ 25/88 Mount Sinai Hospital, New York, Department of Neurology Invited Lecturer: Implant-induced sprouting in the MPTP-parkinsonian monkeys. 08/12/88 DeWitt Stetten, Jr. Lecture,National Institutes of Health Invited Lecturer: Brain implantation in Parkinson' disease 08/21/88 Aula Padiglione Ponti, University of Milano, Italy. Invited Lecturer: Tissue implantation in MPTP-induced parkinsonian monkeys. 09/23/88 Neurology Department, University of Wien, Austria.

Invited Lecturer: Dopaminergic brain implants in the MPTP primate model. 12/16/88 American College of Neuropsychopharmacology, San Juan.

Invited Speaker: Sprouting of host dopaminergic fibers into the caudate nucleus after solid tissue implantation or injury in MPTP-induced parkinsonian monkeys.

01/27/89 Winter Conference on Brain Research, Snowbird. Chairman: Is the implant-induced sprouting responsible for recovery seen in MPTP-treated monkeys and parkinsonian patients after brain implantation?

08/9/89 IIIrd International Symposium on Neural Transplantation, Cambridge, UK. Chairman: Primate Studies of Graft Function 08/14/89 University of Lund, Department of Medical Cell Research, Sweden

Invited Lecturer: New developments on brain tissue implantation in parkinsonian non-human primates.

12/11/89 University of Rochester, New York Invited Speaker: Progress in brain research: Treatment approaches for neurodegenertive diseases. 04/26/90 First International Congress of Movement Disorders, Washington D.C. Moderator: Brain Implantation 06/21/90 Intracerebral Transplantation in Movement Disorders, Lund, Sweden. Invited Discussant: What have we learnt from studies in monkeys? 09/11/90 NIH Research Day Workshop. Chairman: Transplantation of tissue for neurological disease models. 06/20/91 Ist World Congress of Medical Polonia, Czestochowa, Poland. Invited Speaker: Experimental basis for brain implantation in Parkinson's disease. 10/2/91 Georgetown University, Washington D.C. Invited Speaker: Neural Implantation for Parkinson's Disease. 10/24/91 Departments of Psychiatry & Pharmacology, University of Pennsylvania.

Krystof Bankiewicz

5

Invited Speaker: Future of Brain Implantation for Parkinson's Disease. 12/16/91 Workshop on Neurosurgical Horizons in Parkinson’s Disease, United Parkinson

Foundation, Chicago. Invited Speaker: Comparison of fetal and non-fetal implants. 07/14/92 IVth International Symposium on Neural Transplantation, Washington D.C.

Chairman: Parkinson’s disease: from models to man. 07/15/92 IVth International Symposium on Neural Transplantation, Washington D.C.

Invited Speaker: MPTP-resistant dopaminergic cells in anterior olfactory nucleus and periolfactory area in normal, hemiparkinsonian and fetal mesencephalon implanted monkeys.

10/29/92 XXII Annual Meeting Society for Neuroscience Meeting, Anaheim CA. Chairman: Transplantation I 02/26/93 Barrow Neurological Institute of St. Joseph’s Hospital and Medical Center,

Phoenix. Ground Rounds:.Visiting Professor: Neuroimplants for Parkinson’s Disease

03/13/93 United Parkinson Foundation Workshop on Fetal Transplantation, Chicago Chairman: Grafting for Parkinson’s Disease. Pre-clinical Studies

05/12/93 FDA Chapter of Sigma XI & Society for Experimental Biology and Medicine, D.C. Chapter. Invited Speaker: Brain implantation as a novel treatment for Parkinson’s disease

12/ 10/93 Advances in Clinical Neurosciences I, Rancho Mirage, CA, Invited Faculty: Histopathological outcome of fetal ventral mesencephalon implantation in Parkinsonian patients. 12/24/94 Experimental Biology Meeting, Cajal Club, Anaheim, CA, Invited Speaker: Gene Therapy for Parkinson’s Disease 05/09/94 International Business Communications, Washington, D.C.

Invited Speaker: Use of genetically engineered cell grafting for treatment of Parkinson’s disease.

01/24/95 Winter Conference on Brain Research, Colorado, Invited Speaker: Growth factors in treatment of Parkinson's disease. 02/25/95 Winter Conference on Neuroplasticity, Grenada, West Indes, Invited Speaker:

Neuroimplantation, including gene therapy for treatment of neurodegenerative disorders.

08/29/95 Parkinson’s Disease: A Research Planning Workshop (NIH), Washington, DC, Invited Speaker: Gene Therapy for Parkinson’s disease.

09/20/95 Cellular and Molecular Treatments of Neurological Diseases, Harvard Medical School, Boston, MA. Invited Speaker: Gene therapy approach for treatment of Parkinson’s disease.

10/13/95 The Third Stanford International Neuroscience Symposium, Shanghai, China, Invited Speaker: Primate models of Parkinson’s disease; Genetically engineered cell implantation approach.

11/04/95 Advances in Clinical Neurosciences II, Rancho Mirage, CA, Invited Faculty: Surgical treatments in Parkinson’s Disease. 01/15/96 Models and Treatments of Neurodegenerative Disorders. Verbier, Switzerland.

Invited Speaker: Gene Therapy Approach for Protein Delivery into CNS.

Krystof Bankiewicz

6

01/20/96 Invited Speaker: Network of European CNS Transplantation and Restoration (NECTAR), Rome, Italy. Invited Speaker: Primate models of Parkinson’s disease.

04/09/96 Neuroscience Symposium of Western North Carolina Society of Neuroscience, Invited Speaker: Gene therapy approach for treatment of Parkinson’s disease.

04/12/96 The First Meeting of the Parkinsn’s Disease Gene Therapy Consortium, Washington D.C. Invited Speaker: Application of ex-vivo and in-vivo systems to the primate Parkinson’s model.

10/15/96 The Eight International Catecholamine Symposium, Asilomar CA, Invited Speaker: Utilization of non-human primate model of Parkinson’s disease for gene therapy approach. 10/26/96 Network of European CNS Transplantation and Restoration (NECTAR),

Amsterdam, Holland. Invited Speaker: AAV-mediated gene transfer in MPTP-treated primates.

11/02/96 Advances in Clinical Neurosciences III, Rancho Mirage, CA, Invited Faculty: Ex-vivo and in-vivo gene therapy in the CNS; pros and cons.

06/09/97 First International AAV Symposium, Tokyo, Japan Invited Speaker: In-vivo delivery of genes into CNS using AAV vectors. 10/19/97 International Symposium on Cell and Gene Therapy in Parkinson’s and Other

Neurological Disorders. Beijing, China. Invited Speaker: In-vivo and Ex-vivo Gene Therapy for Parkinson’s Disease.

11/09/97 Advances in Clinical Neurosciences IV, Rancho Mirage, CA, Invited Faculty: Gene Therapy for Parkinson’s Disease;Why? How? When?

03/31/98 Surgical Neurology, NINDS, NIH, Bethesda, MD. Invited Speaker: Gene Delivery into CNS; Therapy for Parkinson’s disease.

08/14/98 Gene Therapy Center, University of North Carolina, Chapel Hill, NC. Invited Speaker: In-vivo gene therapy approach to neurodegenerative disorders.

11/02/98 Biogen Inc. Cambridge MA. Neuroscience Seminars. Invited Speaker: Gene therapy approach for treatment of Parkinson’s disease.

11/16/98 Kagoshima University, Kagoshima, Japan. Invited Faculty: Animal models of Parkinson’s disease; Implications for surgical treatments.

02/26/99 Winter Conference on Neuronal Plasticity, St. Lucia, West Indies. Invited Speaker: Neurosurgical Strategies for Treatment of Parkinson’s Disease

03/18/99 First International Brainstorming Conference on PSP; Bethesda, Maryland. Invited Speaker/Discussant: Novel Treatment Strategies

5/6/99 Neuroscience Program, SUNY, Bufflo,NY Visiting Professor: Gene Therapy Experience

06/12/99 The Armed Forces Institute of Pathology, Washington D.C., Invited Speaker: Animal Models of Human Neurodegenerative Diseases

09/14/99 The Biomedical Engineering Alliance for Connecticut, Plantsville, CT. Invited Speaker: Potential Inracranial Delivery Systems.

10/5/99 Gene Therapy Center, Hanneman University, Philadelphia PA. Invited Speaker: Gene Therapy Approaches to treatment of Parkinson’s Disease.

01/16/00 Neuroregeneration Workshop, Verbie, Switzerland. Invited Speaker: Intracranial Delivery of Therapeutic Genes by AAV Vectors.

01/24/00 Winter Conference on Brain Research, Keystone, CO, Panel Organizer: Can Gene Therapy be Therapeutic? Non-Human Primate Experience

Krystof Bankiewicz

7

02/03/00 George Washington University, Washington D.C. Invited Speaker: Restoration of Dopamine in Parkinson’s Disease by in vivo Gene Therapy

05/20/00 CME Symposium, Movement Disorders and Epilepsy, University of California San Francisco, CA. Guest Speaker: Restorative Therapies for Parkinson’s Disease.

10/23//00 Gene Therapy for Neurological Disorders. Sponsored by the NIH National Institute of Neurological Disorders and Stroke Office of Rare Diseases NIH, Invited Speaker: Dopaminergic recovery following an AAV/AADC approach in parkinsonian primates.

11/02/00 Merck Inc. Invited Speaker: Non-Human Model of Parkinson’s Disease 04/05/01 9th International Catecholamine Symposium, and 5th Internaltional Conference on

Progress in Alzheimer’s and Parkinson’s Disease. Kyoto, Japan. Invited Speaker/Chairman: Restoration of Dopaminergic Function in parkinsonian Monkeys Following AADC Gene Transfer.

05/10/01 Parkinson Institute, Sunnyvale, CA. Guest Speaker : Gene Therapy Approach to Treatment of Parkinson’s Disease.

06/01/01 American Society of Gene Therapy Meeting, Seattle , WA. Invited Speaker: AAV-mediated Long-term Gene Therapy in Parkinsonian Monkeys

07/25/01 Genzyme Inc. Boston MA, Invited Speaker: Gene Delivery into CNS 09/20/01 Department of Neurology Grand Rounds, University of California Davis, Invited

Speaker: Gene Therapy for Parkinson’s Disease. 10/05/01 Elan Pharmaceutical Inc. San Francisco CA. Neurotrophic Approach to Treatment

of Parkinson’s Disease 11/28/01 Genzyme Inc. Boston MA, Invited Speaker: Gene Therapy for Parkinson’s

Disease: Dopaminergic Replacement 01/25/02 Winter Conference on Brain Research, Snowmass CO, Invited Speaker: Cell

Implantation and Gene Therapy Approach to Neurodegenerative Disorders. 05/15/02 Grand Rounds. Neurology Department UCSF, San Francisco. Invited Speaker:

Gene Therapy Approach to Treatment of Parkinson’s Disease. 05/17/02 Parkinson Disease Study Group Meeting, San Diego, CA. Invited Speaker: Gene

Therapy Approach to Parkinson’s Disease. 06/06/02 American Society of Gene Therapy, Boston MA, Invited Speaker: Methods to

Improve Distribution of Vectors and Proteins to CNS. 06/09/02 American Society of Gene Therapy, Boston MA, Invited Speaker: Gene Transfer

Strategies for Treatment of Neuromuscular Disorders. 06/10/02 American Society of Gene Therapy, Boston MA, Chairman: Gene Transfer for

Neuromuscular Disorders 06/14/02 8th International Neurotransplantation and Regeneration Meeting, Keystone CO.

Chairman: Gene Therapy Approaches to CNS 06/17/02 NIH/Taiwan Meeting, Keystone CO, Invited Lecturer: Gene Delivery in CNS 10/13/02 ALS Bio Team, Program for Understanding Neurological Diseases, New York.

Invited Speaker, Chairman: AAV-mediated Gene Transfer. 12/7/02 Hereditary Disease Foundation Workshop, Cambridge, MA: Invited Participant:

Gene Delivery Techniques to CNS 12/11/02 Neural Repair Club, Northwestern University, Chicago IL, Invited Lecturer:

Enzymatic Gene Therapy Replacement in Parkinson’s Disease.

Krystof Bankiewicz

8

02/03/03 The 16th Neuroregeneration Symposia, Keystone CO, Invited Faculty: Future of Gene therapy for Parkinson’s Disease.

03/05/03 Stanley Pruisner Laboratory Seminar Series, San Francisco CA: Application of Gene Transfer Technology to CNS Disorders.

03/29/03 Institute of Neurology and Psychiatry, Warsaw, Poland. Invited Speaker: Gene Therapy Approach to Parkinson’s Disease

06/04/03 Education Session, American Society of Gene Therapy, Washington D.C. Invited Lecturer: Gene Therapy for Parkinson’s Disease; translational approach.

06/05/03 Neural Disorders Workshop, American Society of Gene Therapy, Washington D.C. Invited Speaker: In vivo Imaging of Gene Transfer into CNS.

06/20/03 Modern Imaging Technology, Invited Speaker: Monitoring Parkinson’s Therapy,

11/24/03 ALZA Corporation, Mountain View, CA: Drug Delivery and Targeting Approaches to Treating Unmet Medical Needs in the Central Nervous System Symposium. Invited Speaker: Drug delivery in the Treatment of Parkinson's, Brain Tumors and other CNS Disorders

01/26/04 Winter Conference on Brain Research, Copper Mountain, CO, Invited Speaker: AADC Gene Transfer for Treatment of PD.

02/26/04 Rush-Presbyterian Medical Center, Chicago, IL, Neurology Grand Rounds. Invited Speaker: Gene Therapy for Treatment of Parkinson’s Disease.

03/03/04 University of California San Francisco, Frontiers in Neurology and Neuroscience. Invited Speaker: Gene Therapy for Modifying Levodopa Responsiveness in Parkinson's Disease.

03/03/04 University of California San Francisco, Frontiers in Neurology and Neuroscience. Invited Speaker: Dopaminergic Function and Dyskinesias

10/14/04 Michael J. Fox Foundation for Parkinson’s Research; GDNF Summit. New York, NY. Invited Speaker: Convection-Enhanced Delivery Systems.

10/18/04 Genzyme Corporation, Boston, MA. Invited Speaker: Gene Therapy Approach for CNS Disorders.

11/17/04 University of Pittsburgh, PA. Invited Speaker: Local Delivery of Therapeutics into CNS; Challenges and Future Directions

12/7/04 4th Asia Pacific Symposium on Neural Regeneration, Osaka University, Osaka, Japan. Invited Speaker: AAV/AADC Gene Transfer in Parkinson’s Disease.

12/14/04 NASA-UCSF Biomedical Technology Partnership Workshop, UCSF, San Francisco, CA. Invited Speaker: Drug Delivery into CNS 01/23/05 Winter Conference on Brain Research, Breckenridge, CO. Invited Speaker: Cells,

Genes or Machines: What’s Best for Treating Parkinson’s Disease? 02/17/05 Grand Rounds. Neurosurgery Department UCSF, San Francisco. Invited Speaker:

Neuroimaging of Direct Brain Delivery of Therapeutics 03/07/05 Institute of Neurology and Psychiatry, Warsaw, Poland. Invited Speaker: Novel

Approaches to CNS Delivery of Therapeutic Agents 04/28/05 2005 Lexington Conference on translational Neuroscience, Brain interactive

Devices, Lexington, KY, Invited Speaker: Viral Vector Delivery of Therapeutic Factors

09/01/05 29th Polish Neurological Society Meeting, Lodz, Poland. Invited Speaker: Gene Therapy Advances in Treatment of Parkinson’s Disease.

Krystof Bankiewicz

9

09/05/05 Silesian Medical University, Katowice, Poland. Visiting Professor: Advances in Translational Research.

10/7/05 UCSF Memory & Aging Center, San Francisco, CA. Invited Spearker: “Gene Therapy for Parkinson’s Disease; journey from bench to bedside"

01/18/06 Neurosurgery Residents Research Conference, UCSF, San Francisco, CA, Invited Speaker: CED of Nanoparticles in Neurooncology, Future Directions.

01/24/06 Neurological Sciences Institute, Oregon Health & Sciences University, Portland, OR. Invited Speaker: Gene transfer to CNS: Are we there yet?

02/11/06 Cleveland Clinic Foundation, Cleveland OH, Convection Enhanced Delivery Symposium. Invited Speaker: Novel Catheters for CED.

02/12/06 Cleveland Clinic Foundation, Cleveland OH, Convection Enhanced Delivery Symposium. Invited Speaker: Liposome-based CED Therapeutics.

02/26/06 World Parkinson Congress, Washington DC, Invited Speaker: Long-Term Evaluation of AAV/AADC Gene Transfer in PD Monkeys

02/27/06 Genzyme Corporation, Boston. MA, Invited Lecture: Imaging of Gene Therapy in the Brain

03/14/06 American Medical Writers Association Meeting, Berkeley, CA, Invited Lecture: Gene Therapy for Parkinson’s Disease: Journey from Bench to Bedside

05/10/06 Course Title: PSPG 272A, Advanced Drug Delivery, UCSF, San Francisco, CA, Invited Lecturer: Brain Drug Delivery

06/23/06 6th Polish Medical Congress, Częstochowa, Poland, Invited Speaker: Modern Approaches to Treatment of Brain Tumors

06/24/06 6th Polish Medical Congress, Częstochowa, Poland, Invited Lecture: Gene Therapy for Neurodegenerative Disorders

07/21/06 1ST Annual Western Neurology Specialists’ Symposium, Davis, CA. Invited Speaker: CNS Gene Therapy: Are we there yet?

09/20/06 8th Annual Meeting Udall Centers of Excellence for Parkinson’s Disease Research, Boston, MA Invited Speaker: Gene Therapy for PD

11/16/06 59th Annual Meeting, Gerentological Society of America, Dallas, TX. Organizer and Invited Speaker: Gene Therapy for Parkinson’s Disease, use of primate models

12/0206 4th Annual Huntington Disease Research Symposium, UCSF, San Francisco, CA. Invited Speaker: Imaging of Viral Vector Delivery into CNS

02/01/07 40th Winter Conference on Brain Research, Snowmass, CO Invited Speaker: In vivo Imaging of Gene Therapy

02/17/07 Society of Nuclear Medicine, Mid-Winter Educational Symposium, San Antonio, TX. Invited Speaker: CNS Imaging of Gene Transfer

04/19/07 Translational Neuroscience Meeting, 2007 Lexington Conference, Lexington, KY. Invited Speaker: Viral Vector Gene Transfer

05/19/07 3rd International CED Symposium, Cleveland, OH. Invited Speaker: Real-Time Imaging of CED

07/20/07 Veterinary Western Neurology Specialists Symposium, Davis, CA. Invited Speaker: Gene Therapy Approaches to CNS Disorders

09/05/07 Center for Imaging of Neurodegenerative Diseases, Veterans Administration, San Francisco, CA. Invited Speaker: Image-guided Gene Transfer for CNS Disorders.

Krystof Bankiewicz

10

09/23/07 LIMPE Seminars 2007, Alghero, Sardinia, Italy. Invited Speaker: Experimental Models of Parkinson’s Disease

10/26/07 The 21st Century COE Program 4th International Symposium. Functional Molecules Linked to Neurodegneration and Oncogenesis- Towards Molecular Targeted Therapy, Nagoya, Japan. Invited Faculty: Convection-Enhanced Delivery (CED) of Liposome-Based Drugs for Image-Guided Brain Tumor Treatment

11/02/07 CNS Drug Delivery; Theory to Practice. Satellite Symposium, Society for Neuroscience, San Diego CA. Invited Speaker: Real-Time MR Imaging for Brain Delivery of Viral Vectors/ Nanoparticles.

11/13/07 NIH Workshop: Gene Delivery to the Nervous System. Bethesda, MD. Invited Speaker: Things that can (and most likely will) go wrong when infusing viral vectors into the brain

11/28/07 Cold Spring Harbor Symposium: In Vivo Barriers to Gene Delivery. Cold Spring Harbor Laboratories, NY. Invited Speaker: Use of real time MR imaging for brain delivery of viral vectors

11/30/07 Mayo Clinic Neuroscience Seminar Series. Jacksonville, FL. Visiting Professor: Gene Therapy Approach in Parkinson’s Disease. 12/05/07 Network of European CNS Transplantation And Restoration (NECTAR) Meeting,

Lund Sweden. Invited Speaker: rAAV-AADC in combination with peripheral L-dopa: a pro-drug approach for treatment of Parkinson’s disease.

03/03/08 BioEngineering Program at UCSF, San Francisco, CA. Invited Speaker: Drug Delivery into the Brain.

05/2/08 American Society of NeuroTransplantation and Regeneration, Clearwater, Fl. Invited Speaker: Clinical Results Following AAV2AADC Gene Therapy for PD

06/12/08 The 17th International Conference on Brain Tumor Research and Therapy, Hakodate, Japan, Invited Speaker: Real Time Monitoring for CED of Intratumoral Chemotherapy is Predictive in Canine Spontaneous Gliomas.

09/4/08 The 20th Polish Neurology Congress, Wroclaw, Poland, Invited Presidential Speaker: Gene Therapy Approach in Parkinson’s Disease.

11/05/08 Neurology Frontiers, Grand Rounds Lecture, University of California, San Francisco, CA, Invited Speaker: Promise of Local Drug Delivery in Neurooncology and Neurodegeneration

11/12/08 Pleiades Promoter Project Centre for Molecular Medicine and Therapeutics, Vancouver, B.C. Canada, Invited Speaker: Prospects of Gene Therapy for CNS Disorders.

01/29/09 Winter Conference on Brain Research, Copper Mountain, CO Invited Speaker: Translational Therapeutics: The Quest Progresses

03/20/09 UCSF Memory & Aging Center Seminar Series, San Francisco, CA Invited Speaker: Gene Transfer to the Brain: Will It Ever Work for CNS Disorders?

03/24/09 NINDS Grand Rounds, Bethesda MD. Invited Speaker: Disease Modulating Potential of Gene Transfer In Parkinson's Disease.

05/05/09 The Preston Robert Tisch Brain Tumor Center at Duke, Duke University, Durham NC, Invited Speaker: Imaging of Drug Delivery in Canines with Spontaneous Brain Tumors

Krystof Bankiewicz

11

09/11/09 First International Meeting of the Society for CNS Interstitial Delivery of Therapeutics (SCIDOT). Cleveland Clinic, Invited Speaker: Modeling of Cannula Placement

09/11/09 First International Meeting of the Society for CNS Interstitial Delivery of Therapeutics (SCIDOT). Cleveland Clinic, Invited Speaker: Parkinson’s and Niemann-Pick Diseases

09/30/09 New York Academy of Sciences 2009 MJFF Parkinson’s Disease Therapeutics Conference, New York, Invited Speaker: Image-guided Convective Delivery of AAV Vectors

10/8/09 InBiomed Foundation, San Sebastian, Spain, Invited Faculty: Gene Therapy for Parkinson’s Disease

11/6/09 Hillblom Center for the Biology of Aging, UCSF, San Francisco CA, Invited Faculty: New Ways to Cure Brain Diseases

02/2210 UCSF/UC Berkeley Bioengineering Program, UCSF San Francisco, CA, Invited Faculty: Delivery of Therapeutics Across BBB

03/4/10 Polish Neurosurgical Congress. Ustron, Poland. Invited Faculty: Review of Gene therapy for Parkinson’s Disease

03/5/10 Polish Neurosurgical Congress. Ustron, Poland. Invited Faculty: Image-Guided Delivery of Therapeutics into the Brain

04/37/10 Center for Cerebrovascular Research, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco General Hospital. Invited Speaker: Gene and Drug Delivery into the Brain; Translational Studies

05/18/10 18th International Conference on Brain Tumor Research and Therapy, Travemunde, Germany. Invited Speaker: Optimized Convection-Enhanced Delivery Platform: Experience in Canine Spontaneous Glioma and Non-Human Primates

05/25/10 International Brain Mapping & Intra-operative Surgical Planning Symposium, Bethesda MD. Invited Speaker: Brain Delivery of Drugs and Viral Vectors Under Real Time MRI

TEACHING AND MENTORING = Post-docs, fellows and residents that assist in research in laboratory under Dr. Bankiewicz who provides direction and advice 520 total teaching hours annually. Post-Doctoral Fellows/Residents: 1988-90 Jamie Ullman 1988-90 Steven Skirboll 1989-90 Deniz Perese 1989-92 Jin Wang 1989-91 Jen Sheng 1990-92 Hideki Takubo 1990-92 Daniel Lieberman 1991-92 John Thomas 1992-96 Marina Emborg 1994-96 Shannon Pinkston

Krystof Bankiewicz

12

1994-97 Dea Nagy 1995-96 Ethan Kutzher 1997-99 Yoshigutsu Oiwa 1998-01 Malgorzata Kohutnicka 1998-01 Rosario Sanchez Pernaute 1999-00 John Hamilton 2000-02 John Nguyen 2001-05 Piotr Hadaczek 2002-04 Ryuta Saito 2003-06 Michael Krauze 2004-05 Yoji Yamashita 2004-05 MatyasTamas 2004-06 Mihaela Avramut 2006-09 Louisa Johnston 2006-07 Vanya Varenika 2007-08 Nitasha Sharma 2007-08 Karen Horovitz 2007-07 Alfredo Gimenez 2007-09 Francisco Valles 2008- 10 Adrian Kells 2008- Ernesto Aguilaro 2008-10 Francisco Gimenez 2008-10 Xiomin Su 2009-10 Mark Richardson 2009 Agnieszka Ciesielska 2009-2010 Saif Baig 2010 Waldy San Sebastian 2010 Gabrielle Mittermeyer RESEARCH AWARDS AND GRANTS

ACTIVE

R01 NS050156-04 (Bankiewicz) 08/02/2006 – 06/30/2011 NIH Focal Dopamine Indicated In Dyskinesias In MPTP Monkeys Role: Principal Investigator

P50 CA097257-06 (Berger) 05/01/2007 – 04/30/2012 NIH Brain Tumor SPORE Grant Project 3 (Park): Development Of Novel Lipidic Nanoparticle Therapeutics For Brain Tumor Treatment Role: Co-Investigator R01 NS056107 (Bankiewicz) 08/01/2007 – 07/31/2010 NIH

Krystof Bankiewicz

13

Preclinical Development Of A Gene Therapy For Niemann-Pick Disease, Type A Role: Principal Investigator

R01 NS056107-02S1 (Bankiewicz) 09/01/2009 – 08/31/2010 NIH/ARRA (admin supplement) Preclinical Development Of A Gene Therapy For Niemann-Pick Disease, Type A Role: Principal Investigator

P01 CA118816-01A2 (Berger) 08/27/2007 – 06/30/2012 NIH/NCI Imaging And Tissue Biomarkers In The Treatment of Brain Tumors Project 3 (Bankiewicz): Imaging To Optimize Convection-Enhanced Delivery Role: Co-Investigator P01 CA118816-01A2 (Berger) 08/01/2009 – 07/31/2011 NIH (admin supplement) Imaging And Tissue Biomarkers In The Treatment Of Brain Tumors Role: Co-Investigator Genzyme Corp.Industry Research Contract (Bankiewicz)03/27/2008 – 03/27/2011 Pilot Study Evaluating The Distribution Of AAV 2 Or 4 Into The CNS After ICV Injection In Normal Cynomolgus Monkeys Role: Principal Investigator

Michael J. Fox Foundation (Bankiewicz) 10/01/2008 – 09/30/2010 Image-Guided Convective Delivery Of AAV Vectors Role: Principal Investigator X01 (Bankiewicz) 07/01/2009 – 06/30/2012 NIH-RAID IND-Enabling Studies For AAV2-GDNF For Parkinson's Disease Role: Principal Investigator

RC2 (Federoff) 09/30/2009 – 09/29/2011 NIH A Novel Monkey Model for Parkinson’s Drug Discovery Role: Co-Investigator U01 (Kasahara/UCLA) 07/01/2009 – 06/30/2013 NIH/NINDS Translational Development Of Replication-Competent Retrovirus Vectors Subcontract Co-Investigator Kinetics Foundation (Bankiewicz) 01/01/2007 – 12/31/2013 Translational Studies in CNS Disorders Role: Principal Investigator

Krystof Bankiewicz

14

PENDING

R01 (Bankiewicz) 07/01/2010 – 06/30/2014 NIH (EUREKA) A Nonhuman Primate Model Of Alzheimer's Disease Role: Principal Investigator

U01 (Szoka) 09/01/2010 – 08/31/2015 NIH Glioblastoma Therapy Via Local Delivery Of Nanocarrier Drugs Role: Co-Investigator

Michael J. Fox Foundation (Zhang/Sangamo) 07/01/2010-06/30/2012 Development of a Zinc Finger Protein Therapeutic for the Potential Treatment of Parkinson's Disease Role: Subcontract Principal Investigator

COMPLETED

U54 NS045309 (Federoff/Bankiewicz) 09/30/2002 8/31/2009 NINDS/NIH Parkinson's Disease Gene Therapy Study Group Role: UCSF Principal Investigator

R21 (Bankiewicz PI) NIH/NINDS AAV2 AADC Gene Transfer in Parksinson’s Disease 08/27/2001 06/30/2004

Research Agreement Bankiewicz (PI) 10/01/2001 09/30/2003 Avigen, Inc. Treatment of Diseases of the Central Nervous System with AAV Role: Principal Investigator R01 NS41939 Bodell (PI) 12/15/01 – 11/30/04 NIH DNA Adducts Formed by Dopamine Role: Co-Investigator

BG98039 Bankiewicz (PI) 7/24/98 - 7/31/99 DOE

PET Imaging of Gene Therapy Delivery Role: Principal Investigator

IRP, Bankiewicz (PI) 10/98-1/30/01 NIH, NINDS

Krystof Bankiewicz

15

Identification of Genes Differentially Expressed in the Striatum of PD Rats and Monkeys. Role: Principal Investigator

IRP, Mc Kay (PI) 10/01/99-1/30/01 NINDS, IRP In vitro Generation and Transplantation of Precursor-derived Human Dopamine Neurons Role: Co-Investigator

IRP, Bankiewicz (PI) 10/01/97-1/30/00 NIH, NINDS Effect of Adeno-Associated Virus Mediated Gene Transfer of Aromatic L-amino Acid Decarboxylase Into the Striatum of 6OHDA-lesioned Rats Role: Principal Investigator

IRP, Bankiewicz (PI) 10/01/97-1/30/00 NIH, NINDS, NCI Lentiviral Delivery of AADC Gene in Rodent Model of Parkinson’s Disease. Role: Principal Investigator

IRP, Bankiewicz (PI) 10/01/97-1/30/01 NINDS Methods to Increase Distribution of Therapeutic Agents in the Brain. Role: Principal Investigator

IRP, Bankiewicz (PI) 10/01/97-1/30/01 NIH, NINDS AADC Gene Transfer in Parkinsonian Monkeys. Role: Principal Investigator

IRP, Bankiewicz (PI) 10/01/97-1/30/01 NIH, NINDS Effects of Intrastriatal Implantation of SVG Cells in MPTP-treated Monkeys. Role: Principal Investigator

PUBLICATIONS 1986 1. Bankiewicz K.S., Oldfield E.H., Chiueh C., Jacobowitz D., Doppman J.L., Kopin I.J. (1986)

Hemiparkinsonism in monkeys after unilateral infusion of MPTP. Life Sciences, 39:7-16. 2. Joyce J.N., Marshall J.F. Bankiewicz K.S., Kopin I.J., Jacobowitz D.M. (1986)

Hemiparkinsonism in monkeys after internal carotid artery infusion of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine(MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Research, 382:360-364.

1987

Krystof Bankiewicz

16

3. Barone P., Bankiewicz K.S., Corsini G.U., Kopin I.J., Chase T.N. (1987) Dopaminergic mechanisms in hemiparkinsonian monkeys. Neurology, 37:1592-1595.

4. Saris S.C., Shook D.R., Blaseberg R.G., Dedrick R.L., Doppman J.L., Bankiewicz K.S., Blacklock J.B., Oldfield E.H. (1987) Intracarotid drug delivery with diastole-phased, pulsed infusion. Journal of Neurosurgery, 67:721-726.

5. Schuette W.H., Bankiewicz K.S., Markowitz A., Plowman F.A., Kopin I.J. (1987) A system for measuring the angular response of hemi-parkinsonian monkeys to a food stimulus. Medical Instrumentation, 21:314-316.

1988 6. Bankiewicz K.S., Plunkett R.J., Kopin I.J., Jacobowitz D.M., London W.T. Oldfield E.H.

(1988) Transient behavioral recovery in hemiparkinsonian primates after adrenal medullary allografts. Progress in Brain Research, 78: 543-549.

7. Yang C., Markey S.P., Bankiewicz K.S., London W.T., Lunn G. (1988) Recommended safe practices for using the neurotoxin MPTP in animal experiments. Laboratory Animal Science, 28:563-567.

8. Palombo E., Porrino L.J., Bankiewicz K.S., Crane A.S., Kopin I.J.,Sokoloff L. (1988) Acute administration of MPTP increases local cerebral glucose utilization in the substantia nigra of primates. Brain Research, 453:227-234.

9. Kopin I.J., Bankiewicz K.S., Harvey-White J. (1988) Assessment of brain dopamine metabolism from plasma HVA and MHPG during debresiquin treatment: Validation in monkeys treated with MPTP. Neuropsychopharmacology 1:119-125.

10. Kopin I.J., Bankiewicz K.S., Harvey-White J. (1988) Effect of MPTP-induced parkinsonism in monkeys on the urinary excretion of HVA and MHPG during debrisiquin administration. Life Sciences, 43:133-141.

11. Brücke T., Bankiewicz K.S., Kopin I.J. (1988) The effects of partial dopamine agonist terguride in the MPTP-induced hemiparkinsonian monkey model. European Journal of Pharmacology, 148:445-448.

12. Kopin I.J., White J., Bankiewicz K.S. (1988) A new approach to biochemical evaluation of brain dopamine metabolism. Cellural and Molecular Neurobiology, 8:171-179.

13. Markey S.P., Yang S.C., Johannenssen J.N., Burns R.S., Herkenham M.A, and Bankiewicz K.S. (1988) Mechanisms of MPTP toxicity. Progress in Catecholamine Research, Part B: Central aspects:101-108 Eds. M. Sandlers, A.Dahlstrom and H.Belmaher. Alan R.Liss Inc.

14. Kopin I.J., Bankiewicz K.S., Plunkett R.J., Porrino L., Jacobowitz D.M., London W.T., Oldfield E.H. (1988) Recent advances in dopaminergic implants. Progress in Parkinson Research Edited by Franz Hefti and William J. Weiner. Plenum Publishing Corporation:205-210.

15. Palombo E., Porrino L.J., Bankiewicz K.S., Kopin I.J., Sokoloff L. (1988) Comparison of acute and chronic effects of MPTP on local cerebral glucose utilization in monkeys. Neurotoxicology: Basic and Clinical Research, CIC Edizioni Internazionali, Rome, pp 26-28.

16. Kopin I.J., Bankiewicz K.S., Harvey-White J. (1988) Assessing brain catecholamine metabolism: alterations in MPTP-induced parkinsonism. Proceedings of the National Catecholamine Symposium: 879-882.

17. Kopin I.J., Bankiewicz K.S., Palombo E., Porrino L.J. (1988) Nonmotor aspects of chronic 1-Methyl-4-Phenyl-1,2,3,6- tetrahydropyridine toxicity in primates. Progress in Catecholamine

Krystof Bankiewicz

17

Research, Part B: Central aspects, Eds. M. Sandlers, A. Dahlstrom and H. Belmaher. Alan R. Liss Inc., 109-112.

1989 18. Plunkett R.J., Saris S.C., Bankiewicz K.S., Ikejiri B., Weber R.J. (1989) Implantation of

dispersed cells into primate brain. Journal of Neurosurgery, 70:441-445. 19. Perese D.A., Ullman J., Viola J., Ewing S. and Bankiewicz K.S. (1989) A 6-OHDA-induced

selective parkinsonian rat model. Brain Research, 494:285-293. 1990 20. Bankiewicz K.S., Plunkett R.J., Jacobowitz D.M., Kopin I.J., di Porzio U., London W.T.,

Oldfield E.H. (1990) Fetal dopaminergic implantation in MPTP-parkinsonian monkeys; Histological and behavioral studies Journal of Neurosurgery, 72:231-244.

21. Palombo E., Porrino L.J., Bankiewicz K.S., Crane A.M., Kopin I.J., Sokoloff L.(1990) Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by unilateral intracarotid infusion of the neurotoxin MPTP. The Journal of Neuroscience 10:860-869.

22. Skirboll S.,Wang J., Mefford I., Hsaio J. and Bankiewicz K.S. (1990) Intracerebral microdialysis monitoring of striatal dopamine release and metabolism in MPTP-induced hemiparkinsonian monkeys. Experimental Neurology 110:187-193.

23. Wang J., Saunders R., Aigner T., Hsio J. and Bankiewicz K.S. (1990) Methodology of intracerebral microdialysis in non-human primates. Experimental Neurology 110:181-186.

24. Plunkett R.J., Bankiewicz K.S., Jacobowitz D.M., Kopin I.J., Oldfield E.H. (1990) Effects of adrenal autografting or cavitation only in caudate nucleus of MPTP parkinsonian monkeys. Journal of Neurosurgery 73: 918-926.

25. Miletich R.S., Bankiewicz K.S., Plunkett R.J. (1990) Fetal brain grafts and Parkinson's disease. Science 250:1434-1435. (Letter)

26. Kopin I.J., Bankiewicz K.S., Oldfield E.H., Palmatier M.A., Plunkett R.J. and Porrino L. (1990) Use of MPTP-hemiparkinsonian monkeys to evaluate efficacy of tissue implants as a treatment for Parkinson's disease. Advances in Behavioral Biology Vol. 38. In: Basic and Clinical Therapeutic Aspects of Alzheimer’s and Parkinson's Diseases, Vol. 1; Eds. T. Nagatsu, A. Fisher and M Yoshida, 769-775.

27. Bankiewicz K.S., Plunkett R.J., Mefford I.,Kopin I.J., Oldfield E.H. (1990) Behavioral recovery from MPTP-induced parkinsonism in monkeys after intracerebral tissue implants is not related to CSF concentrations of dopamine metabolites. Progress in Brain Research 82: 561-571.

1991 28. Bankiewicz K.S., Plunkett R.J., Jacobowitz D.M., Kopin I.J. and Oldfield E.H. (1991)

Sprouting-induced recovery from MPTP-induced parkinsonism in primates after fetal non- dopaminergic brain implants; Histochemical and behavioral studies. Journal of Neurosurgery 74: 97-101.

29. Bankiewicz K.S., Plunkett R.J., Oldfield E.H. (1991) Tissue grafting and immunosuppression. Journal of Neurosurgery 74:158-159. (Letter)

Krystof Bankiewicz

18

30. Bankiewicz K.S., Oldfield E.H., Plunkett R.J., Schuette W.H., Cogan D.G., Hogan N., Kopin I.J. (1991) Apparent unilateral visual neglect in MPTP-hemiparkinsonian monkeys is due to delayed initiation of motion. Brain Research, 541:98-102.

31. Herkenham M., Little M.D., Bankiewicz K.S., Yang S.C., Markey S.P., Johannessen J.N. (1991) Selective retention of MPP+ within the monoaminergic system of the primate brain following MPTP administration: An in vivo autoradiographic study. Neuroscience, 40:133-158.

32. Bankiewicz K.S. Neural implantation in Parkinson's Disease; More questions than answers. (1991) Polski Tygodnik Lekarski

33. Palombo E., Porrino L.J., Crane A.M., Bankiewicz K.S., Kopin I.J. and Sokoloff L. (1991) The cerebral effects of monoamine inhibition in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) acutely treated monkeys. Journal of Neurochemistry, 56:1639-46.

34. Wang J., Bankiewicz K.S., Plunkett R.J., Sheng, J. and Jacobowitz D.M.(1991) . Transplantation of microglia reduces experimental parkinsonism in rats. Intracerebral Transplantation in Movement Disorders. Eds. O. Lindvall, A. Björklund, H. Widner. Elsevier Science Publishers B.V., 313-323.

35. Bankiewicz K.S. (1991) Primate MPTP-induced parkinsonism. Methods in Neurosciences, Vol.7, 168-182.

1992 36. Brücke T., Danielczyk W., Muller Ch., Wenger S., Bankiewicz K.S., Deecke L. (1992).

Terguride: Experimentelle und klinische ergebnisse 37. Kordower J. Bankiewicz K.S. and Mufson E. NGF receptor (p75)-immuno-reactivity within

hypoglossal motor neurons following axotomy in monkeys.(1992) Restorative Neurology and Neuroscience, 4: 411-417

1993 38. Kopin I.J., Bankiewicz K.S., Plunkett R.J., Jacobowitz D.M., Oldfield E.H. Tissue implants

in treatment of parkinsonian syndromes in animals and implications for use of tissue implants in humans. (1993) Adv Neurol, 60:707-14

39. Miletich R.S., Bankiewicz K.S., Kopin I.J., Plunkett R.J., Adams R., Dunn B., Di Chiro G. Metabolism and PET imaging of 6-[F-18] Fluoro-L-Dopa after Catechol-O- Methyltransferase inhibition in normal and hemiparkinsonian monkeys. (1993) Brain Research, 626:1-13

40. Bankiewicz K.S., Mandel R., Sofroniew M.V. Trophism, transplantation and animal models of Parkinson’s disease. (1993) Experimental Neurology, 124: 140-149

1994 41. Miletich R.S., Bankiewicz K.S., Quarantelli M., Plunkett R.J., Frank J., Di Chiro G., Kopin

I.J. (1994) MRI detects acute degeneration of the nigrostriatal dopamine after MPTP in hemiparkinsonian monkeys. Annals of Neurology, 35 (6):689-687

42. Wang J., Lieberman D.M., Takubo H., Finberg J. and Bankiewicz K.S. The effects of gliosis on dopamine metabolism in rat striatum. (1994) Brain Research, 663: 199-205.

Krystof Bankiewicz

19

43. Thomas J., Wang J., Takubo H., Sheng J., Jesus S. and Bankiewicz K.S. A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization. (1994) Experimental Neurology 126: 1-10

44. Wang J., Bankiewicz K.S., Plunkett R.J., Chen C., Oldfield E.H. Intrastriatal implantation of Interleukin 1. Reduction of parkinsonism in rats by enhancing neuronal sprouting from residual dopaminergic neurons in the ventral tegmental area of the midbrain. (1994) Journal of Neurosurgery 80:484-490.

45. Bankiewicz K.S., Palmatier M., Plunkett R.J.,Cummins A., Oldfield E.H. Amnion implantation into caudate reverses the hemiparkinonian syndrome in non-human primates (1994) Journal of Neurosurgery 81:53-60.

46. Beluzzi J.D., Domino E.F., May J.M., Bankiewicz K.S., McAfee D.A., N-0923, a selective dopamine D-2 receptor agonist, is efficacious in rat and monkeys models of Parkinson’s disease. (1994) Mov. Disorder 9:147-54

1995 47. Lieberman D.M., Laske D.W., Morrison P., Bankiewicz K.S., Oldfield E.H. Convection-

enhanced distribution of large molecules in gray matter during interstitial infusion. (1995) Journal of Neurosurgery 82: 1021-1029.

48. Finberg J.P.M., Wang J., Goldstien D.S., Kopin I.J. and Bankiewicz K.S. Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. Journal of Neurochemistry 65: 1213-1220.

1997 49. Eberling J.L., Bankiewicz K.S., Jordan S., VanBrocklin H.F., O'Neil J.P., Emborg M., and

Jagust W.J. (1997) Pet [18F]6-fluoro-l-m-tyrosine imaging of MPTP-lesioned primates. Brain Research: 750:264-276

50. Bankiewicz K.S., Leff S., Nagy D., Jungles S., Rokovich J, Spratt K., Cohen L, Libonati M, Richard O. Snyder R.O, Mandel R. (1997) Practical Aspects of the Development of Ex vivo and In Vivo Gene Therapy for Parkinson’s Disease. Experimental Neurology: 144/1; 147-156.

51. Eberling J, Bankiewicz K.S. Jordan S, Bringas JR, McLaughlin WW, Pivirotto P, and Jagust W. (1997) Positron emission tomography (PET) evidence of nigrostriatal pathway degeneration in MPTP -treated monkeys; a model of MPTP-induced degeneration of the dopaminergic system. Neuroreport: 8; 2727-2733

1998 52. Finberg J.P, Wang J. Bankiewicz, K.S., Harvey-Ehite J., Kopin I.J., Goldstein D.S. (1998)

Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J. Neural. Transm. Suppl. 1998; 52: 279-285.

53. Kordower J.H., Hanbury R and Bankiewicz K.S. (1998) Neuropathology of cell transplants in patients with Parkinson’s disease. Cell Transplants for Neurological Disorders, Humana Press, 51-75

54. Jordan, S., Bankiewicz, K.S., Eberling, J.L., VanBrocklin, H.F., O'Neill, J.P., Jagust, W.J. (1998). An in vivo microdialysis study of striatal 6-[18F]fluoro-L-m tyrosine metabolism. Neurochemical Research. 23:517-521.

Krystof Bankiewicz

20

55. Bankiewicz, K.S., Bringas J.R., McLaughlin W., Pivirotto P., Hundal R., Yang B., Emborg M.E., Nagy D. (1998) Application of gene therapy for Parkinson’s disease; non-human primate experience. Adv Pharmacology. 42:801-806

56. Eberling J.L, Jagust W.J., Taylor S., Bringas J., Pivirotto P., VanBrocklin H.F. and Bankiewicz K.S. (1998) A Novel MPTP primate model of Parkinson’s disease: neurochemical and clinical changes. Brain Res. 805:259-262

1999 57. Eberling J.L, Major E.O., Nagy D and Bankiewicz K.S. (1999) Genetic Engineering for

Parkinson;s disease. CNS Regeneration. Basic Science and Clinical Advances. Academic Press. 437-454.

58. Eberling J.L., Bankiewicz, K.S., Pivirotto P., Bringas J., Chen K., Nowotnik D.P., Steriner, J.P., Budinger T.F., Jagust W.J. Dopamine transporter loss and clinical changes in MPTP-lesioned primates. (1999) Brain Research 832; 184-187.

59. Bankiewicz K.S., Sanchez-Pernaute R., Oiwa Y., Kohutnicka M., Cummins A., Eberling J.L. Animal models of Parkinson’s diesease. Current Methods in Neurosciences (1999) 9.4:1-32.

2000 60. Cunningham J, Oiwa Y, Nagy D, Podsakoff G, Colosi P, Bankiewicz K.S..Distribution of

AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant. 2000 Sep-Oct;9(5):585-94.

61. Bankiewicz K.S., Bringas J, Pivirotto P, Kutzscher E, Nagy D, Emborg M.E.. Technique for bilateral intracranial implantation of cells in monkeys using an automated delivery system. Cell Transplant. 2000 Sep-Oct;9(5):595-607.

62. Quereshi N.H., Bankiewicz K.S., Louis D.N., Hochberg F.., Chiocca A., Harsh G.R. Multicolumn infusion of gene therapy cells into human brain tumors: technical report. (2000) Neurosurgery 46 (3) 633:669.

63. Bankiewicz K.S., Eberling J.L., Kohutnicka M., Jagust W.J., Pivirotto P., Bringas J., Cuningham J., Budinger T.F., Harvey White J. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in-vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. (2000) Experimental Neurology Jul;164(1):2-14.

64. Eberling J.L., Pivirotto P., Bringas J., and Bankiewicz K.S. Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys. (2000) Experimental Neurology 165, 3342-364.

65. Litvan I., Dickson D., Ennever J., Delacourte A., Hutton M., Dubois B., Golbe L., Hallett M., Schellenberg G., Standaert, Brooks D., Price D., Bankiewicz K.S. Research goals in progressive supranuclear palsy: a brainstorming conference. (2000) Movement Discorders, 15 (3); 446-458.

2001 66. Bankiewicz K.S., Pernaute R.S., Pivitotto P. Major E. (2000) Ex-vivo gene therapy for

treatment of Parkinson’s Disease. (2001) Methods in Molecular Medicine 62: 269-278. 67. Hamilton J.F., Morrison P.F., Chen M.Y., Harvey-White J, Pernaute R.S., Phillips H.S.,

Oldfield E.H., and Bankiewicz K.S. Heparin Co-infusion during Convection-Enhanced

Krystof Bankiewicz

21

Delivery (CED) increases the distribution of the glial derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. (2001) Experimental Neurology 168, 155-161.

68. Bang Nguyen J, Sanchez-Pernaute R. Cunningham J. and.Bankiewicz KS. Heparin combined with convection-enhanced delivery increases AAV-2-mediated gene transfer of TK in the rat brain. (2001) NeuroReport. 12 (9) 1961-4.

69. Sánchez-Pernaute R, J Harvey-White, Cunningham J and Bankiewicz KS. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6OHDA-lesioned rats. (2001) Molecular Therapy; 4 (4):324-30.

70. Bankiewicz KS, Sanchez-Pernaute R, Oiwa Y, Kohutnicka M, Cummins A, Eberling J. Preclinical models of Parkinson's disease. Curr Protoc Neurosci. 2001 May; Chapter 9:Unit9.4.

71. Sánchez-Pernaute R, Studer L., Bankiewicz K. S., Major E. McKay R.D.G. In vitro generation and transplantation of precursor-derived human dopamine neurons. (2001) J. Neurosci. Res. 65 (4); 284-8.

2002 72. Kim JH, Auerbach JM, Rodriguez-Gomez JA, Velasco I, Gavin D, Lumelsky N, Lee SH,

Nguyen J, Sanchez-Pernaute R, Bankiewicz K, McKay R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. (2002) Nature. Jul 4; 418(6893):50-6

73. Eberling JL, Pivirotto P, Bringas J, Steiner JP, Kordower JH, Chu Y, Emborg ME, Bankiewicz KS. The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys. Exp Neurol. 2002 Dec;178(2):236-42.

2003 74. Emborg ME, Tetrud JW, Moirano J, McLaughlin WW, Bankiewicz KS. Rest tremor in

rhesus monkeys with MPTP-induced parkinsonism. Front Biosci. 2003 May 1;8:a148-54 75. Oiwa Y, Sanchez-Pernaute R, Harvey-White J, Bankiewicz KS. Progressive and extensive

dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease. J Neurosurg. 2003 Jan;98(1):136-44

76. Oiwa Y, Eberling JL, Nagy D, Pivirotto P, Emborg ME, Bankiewicz KS. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Front Biosci. (2003) Sep 1;8:a155-66.

77. Goldstein DS, Li ST, Holmes C, Bankiewicz K. Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease. J Pharmacol Exp Ther. 2003 Sep;306(3):855-60.

78. D'Costa J, Harvey-White J, Qasba P, Limaye A, Kaneski CR, Davis-Warren A, Brady RO, Bankiewicz KS, Major EO, Arya SK. HIV-2 derived lentiviral vectors: gene transfer in Parkinson's and Fabry disease models in vitro. J Med Virol. 2003 Oct;71(2):173-82.

79. Eberling JL, Cunningham J, Pivirotto P, Bringas J, Daadi MM, Bankiewicz KS. In vivo PET imaging of gene expression in parkinsonian monkeys. Mol. Ther. 2003 Dec;8(6):873-5.

2004

Krystof Bankiewicz

22

80. Hadaczek P., Hanna Mirek H., Bringas J., Cunningham J., Bankiewicz K.S., (2004) Basic fibroblast growth factor (bFGF) enhances transduction, distribution and axonal transport of adeno-associated virus (AAV-2) vector in the rat brain. Human Gene Therapy, 15:469-479.

81. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS. (2004) Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 2004 Apr 1;64(7):2572-9.

82. Mamot C., Pourdehnad M., Hadaczek P., Bringas J., Nguyen J.B., Saito R., Drummond D.C., Hong K., Kirpotin D.B., Berger M.S., Park J.W., Bankiewicz K.S. (2004) Extensive Distribution of Liposomes in the Central Nervous System delivered by Convection Enhanced Delivery. Journal of Neuro-Oncology 68:1-9.

83. Saito R., Bringas J, Tamas M., Pieper RO, Berger MS and Bankiewicz KS. (2004) Convection Enhanced Delivery of Tumor Necrosis Factor-related Apopotis-inducing Ligand with Systemic Administration of Temozolomide Prolongs Survival in a U87MG Intracranial Xenograft. Cancer Research 2004 Oct 1;64(19):6858-62.

84. Saito R., Bringas, Mirek H., Mitchel S. Berger M.S. and Bankiewicz K.S. Invasive phenotype observed in BCNU-resistant sublines of 9L rat glioma cells – a tumor model mimicking recurrent malignant glioma. Journal of Neurosurgery 2004 Nov;101(5):826-31.

85. Eberling J., Pivirotto, PJ, Bringas,J., Bankiewicz KS. Comparison of two methods for the analysis of [18F]6-fluoro-L-m-tyrosine (FMT) PET data. (2004) Neuroimage, 23;358-63

86. Cunningham J, Eberling JL, Sanftner L and Bankiewicz KS. Combinational Treatment Using AAV-AADC Gene Therapy and Oral L-dopa for Parkinson’s Disease. Progress in Gene Therapy, Volume 2. Pioneering Stem Cell/Gene Therapy Trials V S P International Science Publishers, Pub. Date: February 2004 ISBN-13: 9789067643948

2005 87. Krauze, M., Saito. R., Noble C., Tamas M., Bringas J., Bankiewicz K.S. (2005) Reflux-free

cannula for convection-enhanced delivery permitting high-speed delivery of therapeutic agents. Journal of Neurosurgery 103(5); 923-9.

88. Hadaczek P, Mirek H, Berger MS, Bankiewicz K. (2005) Limited efficacy of gene transfer in herpes simplex virus-thymidinekinase/ganciclovir gene therapy for brain tumors. Jouranl of Neurosurgery 2005 Feb;102(2):328-35.

89. Hadaczek P., Daadi M., Bankiewicz K.S., Gene Therapy for Parkinson`s Disease (2005) Prog Neurol Surg, Vol. 18 MS 12 edited by Dr. Andrew Freese et al. S. KARGER AG, BASEL.

90. Saito R, Krauze MT, Bringas JR, Noble C, McKnight TR, Jackson P, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Hong K, Berger MS, Park JW, Bankiewicz KS. (2005) Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol. 2005 Dec;196(2):381-9

91. Saftner L.M., Sommer J.M., Suzuki B.M., Smith P.H., Vijay S., Vargas J.A., Forsayeth J.R., Janet Cunningham J., Bankiewicz K.S., Kao H., Bernal J., Pierce G.F., Johnson, K.W. (2005) AAV2-Mediated Gene Delivery to Monkey Putamen: Evaluation of an Infusion Device and Delivery Parameters. Experimental Neurology, 194; 476-483.

92. Krauze MT, Saito R, Noble C, Bringas J, Forsayeth J, McKnight TR, Park J, Bankiewicz KS. (2005) Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp Neurol. 2005 Nov;196(1):104-11

Krystof Bankiewicz

23

93. Krauze MT, McKnight TR, Yamashita Y, Bringas J, Noble CO, Saito R, Geletneky K, Forsayeth J, Berger MS, Jackson P, Park JW, Bankiewicz KS. (2005) Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc. 2005 Dec;16(1-3):20-6

94. Hadaczek, P., Daadi M and Bankiewicz K.S. (2005) Gene therapy for Parkinson’s Disease. (2005). Principles of Molecular Neurosurgery, Progress in Neurological Surgery, Vol 18: 213-245,

2006 95. Hadaczek P., Kohutnicka M., Krauze MT, Pivirotto P., Cunningham J. Bankiewicz K.S.,

(2006) Convection Enhanced Gene Transfer and Axonal Transport Following Convection-enhanced Delivery of AAV-2 into the Striatum of Monkeys. Human Gene Therapy. 17(3):291-302.

96. Bankiewicz KS, Daadi M, Pivirotto P, Bringas J, Sanftner L, Cunningham J, Forsayeth JR, Eberling JL. (2006) Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp Neurol. 197(2):363-72.

97. Hadaczek, P., Forsayeth J., and Bankiewicz K.S. (2005) Delivery of molecular therapeutics into the CNS and their distribution within the brain, in Gene Therapy of the Central Nervous System: From Bench to Bedside, Kaplitt and During eds. Academic Press 121-131.

98. Yamashita Y, Saito R., Krauze MT, Kawaguchi T. Noble C., Drummond DC, Kirpotin DB, Pieper RO, Park JW, Bankiewicz KS. (2006) Convection-Enhanced Delivery of Liposomal Doxorubicin in Intracranial Brain Tumor Xenografts. Targeted Oncology, 2006:1:79-85.

99. Saito R., Krauze, MT, Noble CO, Drummond DC, Kirpotin DB, Berger MS, Park JW, and Bankiewicz KS. (2006) Convection-enhanced delivery of Ls-TPT enables an effective continuous low-dose chemotherapy against malignant glioma xenograft model. Neuro-oncol. 2006 Jul;8(3):205-14

100. Saito R,. Krauze MT, Noble C, Tamas M, Drummond DC, Kirpotin DM, Berger MS, Park JW, and Bankiewicz KS (2006) Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. Journal of Neuroscience Methods, 154(1-2):225-32.

101. Hadaczek, P., Mirek, H., Tamas, L., Bohn, M., Noble., C., Park J., Bankiewicz, K.S. (2006) Perivascular pump” driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther. 2006 Jul;14(1):69-7

102. Krauze MT, Noble CO,. Drummond DC, Yamashita Y, Saito R, Berger MS, Kirpotin DM, Bankiewicz KS and Park JW. (2006) Pharmacokinetics, Toxicity, and Efficacy of Liposomal CPT-11 Administered by Convection-enhanced Delivery in Intracranial Brain Tumor Xenografts. Cancer Research 66(5):2801-6.

103. Saito R., Krauze M., Noble C., Drummond D.C., Kirpotin D.B., Park J.W., Berger M.S. and Bankiewicz K.S. (2006) Convection Enhanced Delivery of Liposomal Doxorubicin Eradicate U251MG Intracranial Xenograft. Neuro-oncol. Jul;8(3):205-14.

104. Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, Bringas J, Herscovitch P, Carson RE, Eckelman W, Reutter B, Cunningham J. (2006) Long-term Clinical Improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther. 2006 Oct;14(4):564-70

Krystof Bankiewicz

24

105. Daadi MM, Pivirotto P, Bringas J, Cunningham J, Forsayeth J, Eberling JL and Bankiewicz KS. (2006) Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys. NeuroReport 7(2); 201-4.

106. Sampson JH, Kunwar S,. Friedman AH, Bigner D., Berger MS, Bankiewicz KS (2006) Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus. 2006 Apr 15;20(4)

107. Forsayeth JR, Eberling JL, Sanftner LM, Zhen Z, Pivirotto PJ, Bringas J, Cunningham J, Bankiewicz KS (2006) A Dose-ranging Study of AAV-hAADC Therapy in Parkinsonian Mol Ther. 2006 Oct;14(4):571-7

108. Krauze MT, Forsayeth JR, Park JW, Bankiewicz KS (2006) Real-time imaging and quantification of brain delivery of liposomes Journal of Pharmaceutical Research Pharm Res. 2006 Nov;23(11):2493-504

109. Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, Baker SJ, Bergers G, Pieper RO (2006) The PTEN/Akt pathway dictates the direct αVβ3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Research, 66 (23); 11331-40.

2007 110. Yamashita, Y., Krauze, MT, Kawaguchi, T, Noble, CO, Drummond DC, Park JW,

Bankiewicz, KS (2007) Convection-enhanced delivery of a topoisomerase I inhibitor (nonoliposomal topotecan) and topoisomerease II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro-oncol. Jan;9(1):20-8.

111. Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, Kullberg E, Forsayeth J, Park JW, Bankiewicz KS. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol. 2007 Oct;9(4):393-403

2008

112. Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, and Michael J. Aminoff MJ. (2008) Results from a Phase I Safety Trial of hAADC Gene Therapy for Parkinson’s Disease. Neurology May; 70

113. Dickinson, PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, Larson, RF, Yamashita, Y, Krauze, MT, Noble, CO, Drummond, D, Kirpotin, DB, Park, JW, Mitchel S Berger, MB, Bankiewicz KS (2008) Convection enhanced delivery of liposomes containing CPT-11 monitored with real time magnetic resonance imaging in a canine large animal model system. Journal of Neurosurgery May;108(5):989-998).

114. Krauze MT, Vandenberg SR, Yamashita Y, Saito R, Forsayeth J, Noble C, Park J, Bankiewicz KS. (2007) Safety of real-time convection-enhanced delivery of liposomes to primate brain: A long-term retrospective. Exp. Neurol 2008 Apr;210(2):638-44..

115. Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS. (2008) Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics. 2008 Jan;5(1):123-7.

116. Fiandaca M, Forsayeth J, Bankiewicz K. (2008) Current status of gene therapy trials for Parkinson's disease. Exp Neurol. 2008 Jan;209(1):51-7

117. Forsayeth JR, Bankiewicz KS (2008). Development of AAV2-hAADC Gene Therapy for

Krystof Bankiewicz

25

Parkinson’s Disease Designed to Enhance Dopamine Metabolism. Jpn J Neurosurgery 17 (4) 323-4.

118. Cunningham J, Pivirotto P, Bringas J, Suzuki B, Vijay S, Sanftner L, Kitamura M, Chan C, Bankiewicz KS Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.. Mol Ther. 2008 Jul;16(7):1267-75.

119. Richardson RM, Larson PS, Bankiewicz KS. Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models. Neurosurgery. 2008 Oct;63(4):629-442.

120. Krauze MT, Vandenberg SR, Yamashita Y, Saito R, Forsayeth J, Noble C, Park J, Bankiewicz KS. Safety of real-time convection-enhanced delivery of liposomes to primate brain: a long-term retrospective. Exp Neurol. 2008 Apr;210(2):638-44.

121. Varenika V, Dickinson P, Bringas J, LeCouteur R, Higgins R, Park J, Fiandaca M, Berger M, Sampson J, Bankiewicz K. Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg. 2008 Nov;109(5):874-80.

122. Kikuchi T, Saito R, Sugiyama S, Yamashita Y, Kumabe T, Krauze M, Bankiewicz K, Tominaga T. Convection-enhanced delivery of polyethylene glycol-coated liposomal doxorubicin: characterization and efficacy in rat intracranial glioma models. J Neurosurg. 2008 Nov;109(5):867-73.

2009 123. Anatomical compression due to high volume convection enhanced delivery. Valles F,

Fiandaca MS, Bringas J, Dickinson P, LeCouteur R, Higgins R, Berger M, Bankiewicz KS. Neurosurgery. 2009 Sep;65(3):579-85; discussion 585-6.

124. Yin D, Valles FE, Fiandaca MS, Forsayeth J, Larson P, Starr P, Bankiewicz KS. Striatal volume differences between non-human and human primates. J Neurosci Methods. 2009 Jan 30;176(2):200-5.

125. Johnston LC, Eberling J, Pivirotto P, Hadaczek P, Federoff HJ, Forsayeth J. BankiewiczKS. Clinically relevant effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged Rhesus monkeys. Hum Gene Ther. 2009 Feb 9

126. Kells AP, Hadaczek P, Yin D, Bringas J, Varenika V, Forsayeth J, Bankiewicz KS. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2407-11.

127. Eberling J, Kells AP, Pivirotto P, Beyer J, Bringas J, Federoff HJ, Forsayeth J, Bankiewicz K. Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys. Hum Gene Ther. 2009 Mar 2.

128. Yasuhara T, Matsukawa N, Koichi Hara, Maki M, Ali MM, Yu S, Bae E, Yu G, Lin Xu, McGrogan M, Bankiewicz K, Case C, Borlongan CV Notch-induced rat and human bone marrow stromal cell grafts reduce ischemic cell loss and ameliorate behavioral deficit in chronic stroke animals. Stem Cells Dev. 2009 Dec;18(10):1501-14.

129. Luz M, Dugich-Djordjevic M, Bringas J, Hadaczek P, Johnson GA, Grahn AY, Eastman S, Bankiewicz KS. Non-PEGylated Liposomes for Convection-Enhanced Delivery of Topotecan and Gadodiamide in Malignant Glioma: Initial Experience Journal of NeuroOncology, 2009 Nov;95(2):185-97.

130. Varenika V, Kells AP, Valles F, Hadaczek P, Forsayeth J, Bankiewicz KS. Controlled dissemination of AAV vectors in the primate brain. Prog Brain Res. 2009;175:163-72.

Krystof Bankiewicz

26

131. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, Vanbrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009 Oct 14.

132. Richardson RM, Varenika V, Forsayeth JR, Bankiewicz KS. Future applications: gene therapy. Neurosurg Clin N Am. 2009 Apr;20(2):205-10. Review.

133. Su X, Kells AP, Huang EJ, Lee HS, Hadaczek P, Beyer J, Bringas J, Pivirotto P, Penticuff J, Eberling J, Federoff HJ, Forsayeth J, Bankiewicz K. Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus Monkeys. Hum Gene Ther. 2009 Aug 11.

134. Hadaczek P, Forsayeth J, Mirek H, Munson K, Bringas J, Pivirotto P, McBride JL, Davidson BL, Bankiewicz KS. Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther. 2009 Mar;20(3):225-37.

135. Fiandaca MS, Varenika V, Eberling J, McKnight T, Bringas J, Pivirotto P, Beyer J, Hadaczek P, Bowers W, Park J, Federoff H, Forsayeth J, Bankiewicz KS. Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage. 2009 Aug;47 Suppl 2:T27-35. Epub 2008 Nov 27.

136. Krauze MT, Forsayeth J, Yin D, Bankiewicz KS. Convection-enhanced delivery of liposomes to primate brain. (2009) Methods in Enzymology, Vol. 465, Burlington: Academic Press; 349-362.

137. Yin D, Valles FE, Fiandaca MS, Bringas J, Gimenez F, Berger MS, Forsayeth J, Bankiewicz KS. Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. NeuroImage. 2009 Sep 15.

2010 138. Dickinson, PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, Larson, RF,

Yamashita, Y, Krauze, MT, Noble, CO, Drummond, D, Kirpotin, DB, Park, JW, Mitchel S Berger, MB, Bankiewicz KS.(2010) Canine spontaneous glioma: A translational model system for convection-enhanced delivery. NeuroOncology May 20 (in press)

139. Kato T, Natsume A, Iwamizu H, Sugita T, Hachisu R, Nakano Y, Watanabe R, Yuki k, Motomura K, Bankiewicz K, Wakabayashi T. Efficient delivery of liposome-mediated O6-methylguanine-DNA methyltransferase-siRNA reinforces the cytotoxity of temozolomide in grade IV glioma stem cells. Gene Therapy. 2010 Jun 3 (in press)

140. Yin D, Forsayeth J, Bankiewicz KS. Optimized cannula for convection-enhanced delivery in rat brain. Journal of Neuroscience Methods, Mar 15;187(1):46-51

141. Valles F, Fiandaca MS, Eberling JL, Starr PA, Larson PS, Christine CW, Forsayeth J, Richardson MR, Su X, Aminoff MJ, Bankiewicz KS. Qualitative Imaging of AAV2-hAADC Gene Therapy in a Phase I Study for the Treatment of Parkinson's Disease. Neurosurgery (in press)

142. Yin D, Richardson M, Fiandaca MS, Bringas J, Forsayeth J, Berger MS, Bankiewicz KS. Cannula Placement for Effective Convection-enhanced Delivery in the Non-Human Primate Thalamus and Brainstem: Implications for Clinical Delivery of Therapeutics. Journal of Neurosurgery. 2010, Apr 2

143. Hadaczek P, Johnston L, Forsayeth J, Bankiewicz KS. Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain.

Krystof Bankiewicz

27

Neuropharmacology Jun; 58(7):1114-21. 144. Richardson M Gimenez F, Aguilar-Salegio E, Bringas J, Berger MS, Krystof S.

Bankiewicz KS. T2 Imaging for Prediction and Monitoring of Intraparenchymal Real-time Convection Enhanced Delivery. Journal of Neurosurgery (in press)

145. Martínez-Cerdeño V, Noctor SC, Espinosa A, Ariza J, Parker P, Orasji S, Daadi MM, Bankiewicz K, Alvarez-Buylla A, Kriegstein AR.Embryonic MGE precursor cells grafted into adult rat striatum integrate and ameliorate motor symptoms in 6-OHDA-lesioned rats. Cell Stem Cell. 2010 Mar 5;6(3):238-50.

146. Gimenez F, Krauze MT, Valles F, Hadaczek P, Bringas J, Sharama N, Forsayeth J, Bankiewicz KS. Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage. 2010 Jan 18.

147. Kells AP, Eberling J, Su X, Pivirotto P, Bringas J, Hadaczek P, Narrow WC, Bowers WJ, Federoff HJ, Forsayeth J, Bankiewicz KS. (2010) Regeneration of the MPTP-lesioned Dopaminergic System after Convection-enhanced Delivery of AAV2-GDNF. Journal of Neuroscience (in press),

148. Aguilar-Salegio E, Kells A P, Richardson RM, Hadaczek P, Forsayeth J, Bringas J, Sardi PS, Passini M, Shihabuddin L, Fiandaca M S, Bankiewicz K S. MRI-controlled delivery of AAV2 to the primate brain for the treatment of lysosomal storage disorders. Human Gene Therapy (in press).

149. Su X, Kells AP, Aguilar-Salegio A, Richardson M, Hadaczek P, Beyer J, Bringas J, Pivirotto P, Forsayeth J, Bankiewicz KS, MRI Predicts Distribution of GDNF in the NHP Brain After Convection-enhanced Delivery of AAV2-GDNF. Molecular Therapy (in press)

150. Fiandaca MS, Aguilar-Salegio E, Yin D, Richardson MR, Valles F, Larson PS, Starr PA, Lonser RR, Bankiewicz KS. Comparative analysis of MRI-determined AC-PC line measurements in non-human primates and humans; clinical implications. Neurosurgery (in press)

151. Krauze MT, Noble CO, Hadaczek, P, Drummond DC, Forsayeth JR, Beyer J, Kirpotin DB, Berger MS1, Bankiewicz KS, Park JW (2009) Treatment of an Intracranial U87 Rodent Model with Nano-liposomal CPT-11. NeuroOncology (submitted)

152. Hadaczek P, Eberling JL, Pivirotto P, Bringas J, Forsayeth J, Bankiewicz KS. (2010) Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Molecular Therapy (in press)

153. Liu Y, Paliwal S, Bankiewicz KS, Bringas JR, Heart G, Mitragotri S, Prausnitz MR. Ultrasound-Enhanced Drug Transport and Distribution in the Brain. AAPS PharmSciTech. 2010 Jun 8